Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report)’s stock price shot up 1.5% on Friday . The stock traded as high as $13.65 and last traded at $13.65. 2,480 shares were traded during trading, an increase of 3% from the average session volume of 2,398 shares. The stock had previously closed at $13.45.
Finch Therapeutics Group Stock Performance
The firm has a market cap of $21.92 million, a price-to-earnings ratio of -1.55 and a beta of 1.21. The company’s fifty day moving average is $13.14 and its two-hundred day moving average is $12.21.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Featured Articles
- Five stocks we like better than Finch Therapeutics Group
- How is Compound Interest Calculated?
- How to Build the Ultimate Everything ETF Portfolio
- What Are the U.K. Market Holidays? How to Invest and Trade
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
